| abstract |
DGAT-1 inhibitor compounds of the formula (I) and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions, processes for making them and their use in the treatment of, for example, obesity are described: (see formula (I)) where n is 0, 1, 2 or 3, R is independently selected from fluoro, chloro, bromo, trifluoromethyl, methoxy, difluoromethoxy and trifluoromethoxy and z is carboxy or a mimetic or bioiso ester thereof, hydroxy, hydroxymethyl, or -CONRbRc where in the present Rb and Rc are independently selected from hydrogen and alkyl (1-4C), said alkyl groups (1-4C) can be optionally substituted by carboxy or mimetic or bioisystem thereof. |